Home
Diseases
Head and Neck Cancer

Head and Neck Cancer

Disease

Also known as: oral head and neck cancer

Related News

CEL-SCI to Begin U.S. Registration Study for Multikine in Summer 2026, Pursues Saudi Partnership

Jun 12, 2026

CEL-SCI plans to start patient enrollment in summer 2026 for a 212-patient U.S. registration study of its cancer immunotherapy Multikine, with the goal of seeking early accelerated approval. The company is also advancing a strategic partnership with Saudi Amarox to commercialize Multikine in Saudi Arabia, where it has submitted a Breakthrough Medicine Designation application. These initiatives build on Phase 3 data showing Multikine improved 5-year survival in head and neck cancer patients from 45% to 73%.

Ultra-Low-Dose Immunotherapy Shows Clinical Activity Across Multiple Trials

May 27, 2026

Three trials show ultra-low-dose checkpoint inhibitors retain efficacy with reduced toxicity and dramatically lower costs. DELII and Patil et al. trials tested low-dose nivolumab in solid tumors and HNSCC; NIVIPIT tested intratumoral low-dose ipilimumab in melanoma.

CEL-SCI plans summer 2026 enrollment in Multikine head and neck cancer registration study

May 14, 2026

CEL-SCI said it expects to begin summer 2026 enrollment in a 212-patient U.S. confirmatory registration study of Multikine in head and neck cancer. The company also said it submitted a Breakthrough Medicine Designation application in Saudi Arabia and reported quarterly net loss of $5.5 million.

GeoVax Advances Gedeptin Toward Phase 2 Trial, Secures Emory License for ICI Combination

Apr 29, 2026

GeoVax is advancing Gedeptin toward a Phase 2 trial in head and neck cancer and has secured an exclusive license from Emory University for Gedeptin-ICI combination technology. The therapy has Orphan Drug Designation for oral and pharyngeal cancers.

Structural Nanomedicine Vaccine Shows Promise Against HPV-Driven Cancers in Preclinical Study

Apr 07, 2026

A novel therapeutic vaccine using structural nanomedicine principles has shown promising results against HPV-driven cancers in preclinical models. The spherical nucleic acid vaccine design significantly slowed tumor growth and extended survival by generating potent T-cell responses. Unlike preventive HPV vaccines, this approach is designed to treat established cancers caused by the virus.

Immunotherapy Expands to Earlier Cancer Stages Across Multiple Tumor Types

Mar 24, 2026

Immunotherapy is increasingly used in earlier cancer stages before or after surgery across seven tumor areas. Research shows neoadjuvant and adjuvant immunotherapy can reduce recurrence risk and improve immune recognition of tumor cells. However, challenges remain including side effects, costs, and determining which patients benefit most from earlier treatment.

FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma

Mar 19, 2026

The U.S. FDA has granted Fast Track designation to FluoGuide's FG001 as an intraoperative imaging agent for high-grade glioma surgical resection. The designation follows IND clearance in January and enables accelerated development and regulatory review.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07613723	A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies	RECRUITING	PHASE1
NCT07583914	Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors	NOT_YET_RECRUITING	PHASE1
NCT07583316	A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors	NOT_YET_RECRUITING	PHASE1
NCT07558447	Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy	RECRUITING	NA
NCT07557225	18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors	RECRUITING	NA
NCT07556367	Post-Radiation Oral Health in Underserved Head and Neck Cancer Patients	ACTIVE_NOT_RECRUITING	NA
NCT07550049	Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology	NOT_YET_RECRUITING
NCT07532538	A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions	NOT_YET_RECRUITING
NCT07528495	A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's	RECRUITING	PHASE2/PHASE3
NCT07524894	Staph Nasal Decolonization to Improve Function and Feeding	NOT_YET_RECRUITING	PHASE2